What's Next In Pharma in 2025. Analysing PWC Latest Reports.

2024 was indeed an interesting year. And the pharmaceutical landscape in 2024 is the centre stage of my analysis. Analysing 2024 and predicting trends in 2025.

So I started analysing the most important reports by top consultancy and market research firms in 2024 and here's a complete guide of each of the leading companies's insights.

• Returns Reconstructed: PwC's Opinion

The report "Reinventing for Returns" by PwC stresses the necessity for pharmaceutical companies to radically change their way of doing things. This requires:

1. R&D Investment Strategy: Firms need to reallocate their budget for R&D, doing it the right way by concentrating mostly on "white space" areas, which are the new areas discovered with potential profit and stop digging into crowded R&D pipelines.

2. AI and Digital Technologies: The document draws attention to the potential power of AI, data analytics, and machine learning as key factors in bringing about more rapid drug development and enhanced operational efficiency. To achieve this, companies must base technology choices on process speed and predictive insight.

3. Deals and Collaborations: The role of M&A in 2024 will be no less significant than before while the priority will shift towards collaborations, divestitures, and partnerships. These agreements will not only help in scale and cost efficiencies but also in funding R&D and in the development of new strategies.

4. Trust and Patient-Centric Approach: The report is a reminder of the key role played by trust in the pharmaceutical realm. The companies have to cultivate a patient-centric approach and adhere to the regulations as a way of building long-lasting trust with the external parties involved.

• Targeted Therapies and Gene Modification: ZS Insights

According to ZS's assessment, pharma companies need to focus on 4 factors:

1. Personalized Cell and Gene Therapies: The industry is moving toward personalized therapies, with 3,500-plus precision medicine drugs represented at the upcoming horizon. It is anticipated that transformation will be brought by innovations such as mRNA technology, CRISPR-based treatments, and ADCs (antibody drug conjugates), with oncology and infectious disease management being the primary targets.

2. Precision Medical Treatment: The precision medical treatment will get further attuned to the therapies and provide personal-make of the medicines .

3. Cost Optimization: Being cost-efficient will still be of utmost importance.Most companies are supposed to take out deadwood from products ( outsource what needs to be outsourced and focus on your speciality products or leading Nieche ) , readjust budgets, and use disruptive technologies like generative AI and blockchain for faster clinical trial processes.

4. Public Trust: By meeting customer needs and driving value continuously, the industry can work to rebuild its public trust deficit as the healthcare sector becomes more complex and under the radar, especially after the COVID vaccine's recent facts .

• Trends in Market Access: BioNixus Insights

BioNixus particularizes some of the market access trends, which should be tackled by pharma companies:

1. Self-devoted adoption of the biosimilar: The acceptance of biosimilars will be further propelled, following the demise of rebate walls and vertical integration in the pharmacy benefit managers (PBM) and specialty pharmacy spheres.

2. Long-Term Cost-Focused Approach: The transition of patients to preferable price mechanisms and dismantling of the manufacturers' assistance programs should be viewed more from the long-term perspective .

3. Big Data and Analytics: The big data provides the so-called prescriptive, predictive, and diagnostic analytics that enable the facilitation of new drug development and discovery. so, it makes better decision-making by the linking of big datasets, the detection of patterns, and the prediction of outcomes.

4. Weight Loss Drugs: There is expected to be a good growth rate of the global market of anti-obesity drugs, with this growth being led by the big obesity issue grown in the last few years due to the fact that our medical model of value is pairing off the wrong targets. But the shift to a safer obesity options will be on the rise too.

5. Biotech Layoffs: Despite the fact that biotech startups manage to get a lot of funds, layoffs are being witnessed by big biotech and pharma companies, mainly due to financial issues and market fluctuations.

Global Perspective: AtRadius Insights

Given the projections made by AtRadius, the global pharmaceuticals industry will see a volume and sales increase of 4.6% and 5.1%, respectively, driven primarily by the Asia Pacific market. The expansion is a rebound from a 2023 slowdown following the rapid growth rate recorded in 2021 and 2022.

Long report right? Again Mo will summarize it to you below :)

The steps such as the introduction of perceiving AI, focusing on personalized medications, optimal business models, and addressing public trust should be highly considered.

Key Takeaway for for Pharma Leaders and CEOs

1. Innovate with AI: Use the power of AI and digital technologies to enhance drug development, streamline clinical trials, cut operational costs and for goodness sake in Marketing !

2. Get Together with Personalized Medicine: Channel funds into initiatives such as gene therapy, personalized cell therapies, and precision medicine to offer individuals tailor-made treatments.

3. Public Trust: Educate the patients first, buy into compliance, and bring value, this will add of continuous improvements to business.

4. Emerging Tech Solutions: Embrace the use of big data analytics in decision-making and observe the unfolding of new regulatory frameworks like the EU AI Act ( Compliance is important but this doesn't mean to be scared and stop embracing the new tech. Understand and apply efficiently ).

#Pharmaceuticals #Innovation #HealthcareTech